{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:17:20Z","timestamp":1761488240888},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.ygyno.2009.03.034","type":"journal-article","created":{"date-parts":[[2009,4,27]],"date-time":"2009-04-27T10:57:19Z","timestamp":1240829839000},"page":"42-47","source":"Crossref","is-referenced-by-count":13,"title":["Intraperitoneal access via direct puncture is an alternative way to deliver intraperitoneal chemotherapy in ovarian, fallopian tube and primary peritoneal cancer"],"prefix":"10.1016","volume":"114","author":[{"given":"Chunyan","family":"Lan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2009.03.034_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2009.03.034_bib2","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ygyno.2003.08.010","article-title":"Survival of Californian women with epithelial ovarian cancer, 1994\u20131996: a population-based study","volume":"91","author":"O'Malley","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.03.034_bib3","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","article-title":"Randomized intergroup trial of cisplatin\u2013paclitaxel versus cisplatin\u2013cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results","volume":"92","author":"Piccart","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2009.03.034_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1006\/gyno.2000.5805","article-title":"Long-term results and prognostic factors in patients with epithelial ovarian cancer","volume":"78","author":"Brun","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.03.034_bib5","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2165\/00003495-200161080-00003","article-title":"Intraperitoneal drug delivery of antineoplastics","volume":"61","author":"Markman","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.ygyno.2009.03.034_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1525-1438.2007.00809.x","article-title":"Principles and practice of intraperitoneal chemotherapy for ovarian cancer","volume":"17","author":"Fujiwara","year":"2007","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2009.03.034_bib7","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2009.03.034_bib8","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.03.034_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2009.03.034_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2005.11.013","article-title":"Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"100","author":"Walker","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.03.034_bib11","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/cncr.22467","article-title":"Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer","volume":"109","author":"Marth","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2009.03.034_bib12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/cncr.22466","article-title":"Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses","volume":"109","author":"Elit","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2009.03.034_bib13","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ygyno.2007.02.015","article-title":"Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care","volume":"105","author":"Fung-Kee-Fung","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.03.034_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/gyno.1999.5677","article-title":"Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest","volume":"76","author":"Gadducci","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.03.034_bib15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0020-7292(00)00340-4","article-title":"Intraperitoneal cisplatin-based chemotherapy versus. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer","volume":"72","author":"Yen","year":"2001","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.ygyno.2009.03.034_bib16","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1006\/gyno.1994.1220","article-title":"A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer","volume":"54","author":"Kirmani","year":"1994","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.03.034_bib17","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1158\/1055-9965.EPI-04-0519","article-title":"Body mass index in relation to ovarian cancer survival","volume":"14","author":"Zhang","year":"2005","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.ygyno.2009.03.034_bib18","unstructured":"The NCI common toxicity criteria version 3. Available from URL: http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm 2006. Accessed on 02\/10\/09."},{"key":"10.1016\/j.ygyno.2009.03.034_bib19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00000421-199502000-00005","article-title":"A phase II trial of intraperitoneal high-dose carboplatin and etoposide with granulocyte macrophage-colony stimulating factor support in patients with ovarian carcinoma","volume":"18","author":"McClay","year":"1995","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.03.034_bib20","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1200\/JCO.1998.16.8.2620","article-title":"Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study","volume":"16","author":"Markman","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.03.034_bib21","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1200\/JCO.20.3.694","article-title":"Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up","volume":"20","author":"Barakat","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.03.034_bib22","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0090-8258(03)00377-9","article-title":"First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up","volume":"90","author":"Fujiwara","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.03.034_bib23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1006\/gyno.2000.6108","article-title":"Complications associated with intraperitoneal chemotherapy catheters","volume":"81","author":"Makhija","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.03.034_bib24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0090-8258(91)90266-8","article-title":"Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system","volume":"41","author":"Davidson","year":"1991","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.03.034_bib25","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1525-1438.2005.15304.x","article-title":"Preliminary toxicity analysis of intraperitoneal carboplatin in combination with intravenous paclitaxel chemotherapy for patients with carcinoma of the ovary, peritoneum, or fallopian tube","volume":"15","author":"Fujiwara","year":"2005","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2009.03.034_bib26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ygyno.2007.12.004","article-title":"Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer","volume":"109","author":"Black","year":"2008","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809002017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809002017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,19]],"date-time":"2019-05-19T18:17:32Z","timestamp":1558289852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825809002017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S0090825809002017"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2009.03.034","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}